Biopharmaceutical News and Research

RSS

SBIR grant awarded to develop treatment for alcoholic liver disease-associated hepatorenal syndrome

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine and MitoPower LLC were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism.

9 Nov 2021

Researchers use suction method to deliver SARS-CoV-2 DNA vaccine in lab tests

Rutgers researchers studying COVID-19 have created a new way to deliver DNA molecules into skin cells, using a suction technique similar to the ancient healing practice of cupping.

6 Nov 2021

Yokogawa Acquires Insilico Biotechnology, Developer of Innovative Bioprocess Digital Twin Technology - Enabling solutions for biopharmaceutical development and production -

Yokogawa announces that it has acquired all shares of Insilico Biotechnology AG (“Insilico”), a Stuttgart, Germany-based developer and provider of bioprocess software and services.

From Yokogawa Electric Corporation 3 Nov 2021

Waters and Sartorius partner to help bioprocess scientists accelerate clone selection and process development

Waters Corporation and Sartorius announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.

From Sartorius 3 Nov 2021

Interferon beta-1a plus remdesivir not superior to remdesivir alone in hospitalized COVID-19 patients

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia.

18 Oct 2021

Developing New Technology for the Encapsulation of mRNA-Based Vaccines in Lipid Nanoparticles (LNPs)

NewsMed speaks to KNAUER about the company’s background, its range of specialisms and its pioneering work to facilitate the largescale production of LNPs while meeting the stringent regulations and exacting demands of the biopharmaceutical industry.

From KNAUER Wissenschaftliche Geräte GmbH 14 Oct 2021

New Maternal and Child Health Research Institute launched to improve national health in Singapore

The SingHealth Duke-NUS Maternal and Child Health Research Institute was launched at KK Women's and Children's Hospital (KKH) today by Masagos Zulkifli, Singapore's Minister for Social and Family Development and Second Minister for Health.

8 Oct 2021

Experts address questions on psoriasis patients’ true needs and wellbeing

Almirall S.A., a global biopharmaceutical company focused on skin health, has hosted a scientific session during the 30th EADV Congress which addressed the need and importance to focus on patient wellbeing in real-life clinical practice.

8 Oct 2021

RedShift BioAnalytics Celebrates Opening of StructIR Scientific Services Lab with the Launch of the StructIR Lab Grant Program

RedShift BioAnalytics announced the opening of their scientific services lab, StructIR Lab.

From RedShiftBio 7 Oct 2021

The new FlowCam® LO improves particle characterization in drug development

Yokogawa Fluid Imaging Technologies announces the release of the FlowCam® LO, the first and only light obscuration instrument with imaging capabilities.

From Yokogawa Fluid Imaging Technologies, Inc. 29 Sep 2021

Research paves the way for advances in the treatment of many brain disorders

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.

16 Sep 2021

New RDCA-DAP program launches to accelerate rare disease treatment innovation

The Rare Disease Cures Accelerator-Data and Analytics Platform initiative officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation.

15 Sep 2021

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

19 Aug 2021

Atlas Antibodies acquires evitria

Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.

From Atlas Antibodies AB 28 Jul 2021

PerkinElmer to Acquire Antibody and Reagent Leader BioLegend

PerkinElmer, Inc. today announced it has entered into an agreement to acquire BioLegend, a leading, global provider of life science antibodies and reagents.

From Revvity 27 Jul 2021

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.

22 Jul 2021

Research reveals clues to how a molecule improves appearance of surgery scars

Surgical scars treated with a molecule called alphaCT1 showed a long-term improvement in appearance when compared to control scars, according to multicenter, controlled Phase II clinical trials - a finding that could help surgeons improve patient outcomes.

20 Jul 2021

Redhill Biopharma announces completion of Phase 2/3 COVID-19 study of oral opaganib

RedHill Biopharma Ltd., a specialty pharma company that is a leader in the development of novel oral therapies for COVID-19, today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640) in patients hospitalized with severe COVID-19 pneumonia (NCT04467840). Top-line results are expected in the coming weeks.

20 Jul 2021

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia today announced it has entered into a definitive agreement to acquire LakePharma Inc.

From Curia 14 Jul 2021

Curia to Acquire Integrity Bio, Expanding Biologic Formulation and Fill-Finish Capabilities

Curia today announced it has entered into a definitive agreement to acquire Integrity Bio, Inc., a privately held formulation and fill-finish organization.

From Curia 13 Jul 2021